Management of joint bleeding in hemophilia

Abstract

Hemarthrosis, the hallmark of severe hemophilia, is the major cause of serious bleeding events, disability and reduced quality of life in patients with factor VIII or factor IX deficiency. Joint bleeding is one of the greatest challenges confronting individuals treating hemophilia, and its economic impact is enormous. This article reviews the current management of hemophilic joint bleeding and discusses the potential impact of novel therapies.

Keywords::

• factor IX
• factor replacement
• factor VIII
• hemophilia
• joint bleeding
• prophylaxis